Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03560167 · ClinicalTrials.gov registry record · NA
Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
A NA study, sponsored by Ancora Heart.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT03560167: Completed NA study, sponsored by Ancora Heart.
NCT03560167 is a NA study that has completed, run by Ancora Heart. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03560167, a NA study, has completed, sponsored by Ancora Heart.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a non-randomized, prospective, multi-center Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation.
Primary Outcome
Device-related or procedure-related major adverse events (MAEs)
Interventions
- DEVICE AccuCinch® Ventricular Restoration System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2024-01-28 |
| Phase | NA |
What the finished NCT03560167 record still lists
NCT03560167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which AccuCinch® Ventricular Restoration System is the first listed.
NCT03560167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03560167 about?
NCT03560167 is a clinical study titled "Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation". This is a non-randomized, prospective, multi-center Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation.
What is the current status of trial NCT03560167?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2018-09-24. Estimated completion is 2024-01-28.
What interventions are being tested in trial NCT03560167?
The interventions under investigation include: AccuCinch® Ventricular Restoration System (DEVICE).
Who is sponsoring clinical trial NCT03560167?
This trial is sponsored by Ancora Heart, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03560167's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI